H.-J. Ha et al. / Bioorg. Med. Chem. Lett. 16 (2006) 1880–1883
1883
4. Hannun, Y. A.; Luberto, C.; Argraves, K. M. Biochem-
istry 2001, 40, 4893.
5. Cifone, M. G.; Maria, R. D.; Roncaioli, P.; Rippo, M. R.;
Azuma, M.; Lanier, L. L.; Santoni, A.; Testi, R. J. Exp.
Med. 1994, 180, 1547.
Tachibana, Ogino K. J. Med. Chem. 2003, 46, 3445; (n)
Struckhoff, A. P.; Bittman, R.; Burow, M. E.; Clejan, S.;
Elliott, S.; Hammond, T.; Tang, Y.; Beckman, B. S.
J. Pharmacol. Exp. Ther. 2004, 309, 523; (o) Lu, X.;
Arthur, G.; Bittman, R. Org. Lett. 2005, 7, 1645.
6. Kim, M.; Linardic, C.; Obeid, L.; Hannun, Y. J. Biol.
Chem. 1991, 266, 484.
7. Haimovitz-Friedman, A.; Kan, C. C.; Ehleiter, D.;
Persaud, R. S.; McLoughlin, M.; Fuks, Z.; Kolesnick,
R. N. J. Exp. Med. 1994, 180, 525.
11. (a) Macchia, M.; Barontini, S.; Bertini, S.; Di Bussolo, V.;
Fogli, S.; Giovannetti, E.; Grossi, E.; Minutolo, F.;
Danesi, R. J. Med. Chem. 2001, 44, 3994; (b) Machida,
M.; Bertini, S.; Fogli, S.; Giovannetti, E.; Minutolo, F.;
Rapposelli, S.; Danesi, R. IL Farmaco 2003, 58, 205.
12. Rerek, M. E.; Chen, H-c; Markovic, B.; Wyck, D. V.;
Garidel, P.; Mendelsohn, R.; Moore, D. J. J. Phys. Chem.
B 2001, 105, 9355.
13. Calculation was carried out with the commercial product
SpartanÒ 04. The overlay structures were deduced by
locking the bonds associated with nitrogen for
comparison.
14. (a) Yun, J. M.; Sin, T. B.; Hahm, H. S.; Lee, W. K.; Ha,
H.-J. J. Org. Chem. 2003, 68, 7675; (b) Kim, J.; Kim, Y.-
W.; Inagakic, Y.; Hwanga, Y.-A.; Mitsutakec, S.; Ryue,
Y.-W.; Lee, W.-K.; Ha, H.-J.; Park, C.-S.; Igarashi, Y.
Bioorg. Med. Chem. 2005, 13, 3475.
8. (a) Karasavvas, N.; Erukulla, R. K.; Bittman, R.; Lock-
shin, R. Eur. J. Biochem. 1996, 236, 729; (b) Jarvis, W. D.;
Fornari, F. A., Jr.; Traylor, R. S.; Martin, H. A.; Kramer,
L. B.; Erukulla, R. K.; Bittman, R.; Grant, S. J. Biol.
Chem. 1996, 271, 8275; (c) Chang, Y. T.; Choi, J.; Ding,
S.; Prieschl, E. E.; Baumruker, T.; Lee, J. A.; Chung, S.
K.; Schultz, P. G. J. Am. Chem. Soc. 2002, 124, 1856.
9. (a) Selzner, M.; Bielawska, A.; Morse, M. A.; Rudiger, H.
A.; Sindram, D.; Hannun, Y. A.; Clavien, P. A. Cancer
Res. 2001, 61, 1233; (b) Fillet, M.; Bentires-Alj, M.;
Deregowski, V.; Greimers, R.; Gielen, J.; Piette, J.; Bours,
V.; Merville, M.-P. Biochem. Pharmacol. 2003, 65, 1366.
10. (a) O’Hagan, D.; Rzepa, H. S. Chem. Commun. 1997, 645;
(b) De Jonghe, S.; Van Overmeire, I.; Gunst, J.; De Bruyn,
A.; Hendrix, C.; Van Calenbergh, S.; Busson, R.; De
Keukeleire, D.; Philippe, J.; Herdewijn, P. Bioorg. Med.
Chem. Lett. 1999, 9, 3159; (c) Azuma, H.; Tamagaki, S.;
Ogino, K. J. Org. Chem. 2000, 65, 3538; (d) He, L.; Byun,
H.-S.; Bittman, R. J. Org. Chem. 2000, 65, 7627; (e) Chun,
J.; He, L.; Byun, H.-S.; Bittman, R. J. Org. Chem. 2000,
65, 7634; (f) Van Overmeire, I.; Boldin, S. A.; Venkatar-
aman, K.; Zisling, R.; De Jonghe, S.; Van Calenbergh, S.;
De Keukeleire, D.; Futerman, A. H.; Herdewijn, P.
J. Med. Chem. 2000, 43, 4189; (g) Chun, J.; Li, G.; Byun,
H.-S.; Bittman, R. J. Org. Chem. 2002, 67, 2600; (h)
Shikata, K.; Azuma, H.; Tachibana, T.; Ogino, K.
Tetrahedron 2002, 58, 5308; (i) Bieberich, E.; Hu, B.;
Silva, J.; MacKinnon, S.; Yu, R. K.; Fillmore, H.;
Broaddus, W. C.; Otterbrite, R. M. Caner Lett. 2002,
181, 55; (j) Chun, J.; Byun, H.-S.; Bittman, R. J. Org.
Chem. 2003, 68, 348; (k) Azuma, H.; Takao, R.; Niiro, H.;
Shikata, K.; Tamagaki, S.; Tachibana, T.; Ogino, K.
J. Org. Chem. 2003, 68, 2790; (l) Dagan, A.; Wang, C.;
Fibach, E.; Gatt, S. Biochim. Biophys. Acta 2003, 1633,
161; (m) Azuma, H.; Takao, R.; Shikata, K.; Niiro, H.;
15. Compound 3. Mp 69–70 °C. 1H NMR (300 MHz, CDCl3)
5.89 (dt, J = 11, 5 Hz, 1H), 5.27–5.37 (m, 2H), 4.47 (t,
J = 8 Hz, 1H), 4.28 (m, 1 H), 4.02 (m, 1H), 2.11 (s, 3H),
1.37 (m, 25H), 0.89 (t, J = 6 Hz, 3 H). FAB Mass: m/z 368
(M++1). Compound 4. Mp 91–92 °C. 1H NMR
(300 MHz, CDCl3) 5.88 (dt, J = 11, 4 Hz, 1 H), 5.23–
5.32 (m, 2H), 4.47 (t, J = 9 Hz, 1H), 4.28 (m, 1H), 4.03 (m,
1 H), 2.35 (q, J = 5 Hz, 2H), 2.08 (q, J = 5 Hz, 2H), 1.37
(m, 23H), 1.14 (t, J = 7 Hz, 3H), 0.89 (t, J = 5 Hz, 3H).
FAB Mass: m/z 382 (M++1). Compound 5. Mp 67–68 °C.
1H NMR (300 MHz, CDCl3) 5.88 (dt, J = 12, 4 Hz, 1H),
5.19–5.33 (m, 3H), 4.44 (t, J = 9 Hz, 1H), 4.26 (m, 1H),
4.01 (m, 1H), 2.34 (t, J = 7 Hz, 2H), 2.07 (q, J = 7 Hz, 2H),
1.68 (m, 3H), 1.24 (m, 48H), 0.89 (t, J = 7 Hz, 3H). FAB
1
Mass: m/z 430 (M++1). Compound 6. Mp 82–83 °C. H
NMR (300 MHz, CDCl3) 8.04 (d, J = 8 Hz, 2H), 7.59 (t,
J = 8 Hz, 1H), 7.46 (t, J = 8 Hz, 2H), 5.96 (m, 2H), 5.55
(m, 2H), 4.49 (t, J = 8Hz, 1 H), 4.38 (m, 1H), 4.05 (m, 1H),
2.08 (q, J = 7 Hz, 2H), 1.24 (m, 22H), 0.89 (t, J = 7 Hz,
3H). FAB Mass: m/z 564 (M++1).
16. van de Loosdrecht, A. A.; Beelen, R. H. J.; Ossenkoppele,
G. J.; Broekhoven, M. G.; Langenhuijsen, M. M. A. C.
J. Immunol. Methods 1994, 174, 311.